Introduction: Type 2 diabetes mellitus (T2DM) is a major public health issue in Iran, affecting 1.3% to 14.5% of the population. Management includes lifestyle modifications, oral antihyperglycemic agents, and insulin therapy. This study compares the efficacy and safety of Novomix insulin with a regimen of insulin glargine and aspart for improving glycemic control in Iranian T2DM patients.
Materials & Methods: A cross-sectional study at Yazd Medical Research Center included participants aged 30 and older with T2DM for over a year. Patients used either Novomix insulin or insulin glargine plus aspart, with specific kidney function criteria (GFR <30). Glycemic control data (HbA1c, fasting blood glucose, and 2hPP glucose) were collected at baseline, 24, and 48 weeks. Ethical approval was granted by Shahid Sadougi University. (IR.SSU. MEDICINE.REC.1399.198).
Results: A total of 243 patients participated, with 130 assigned to the glargine plus aspart group and 113 to the Novomix group. Baseline glycemic measurements were comparable (P>0.05). Both regimens achieved significant reductions in FBG, 2hPP, and HbA1c levels from baseline to 24 and 48 weeks (P<0.05). However, the differences in the changes between the two groups were not statistically significant (P>0.05).
Conclusion: Both insulin regimens effectively lowered glycemic levels without significant differences. Future studies with larger samples and longer durations are needed for further evaluation.